Premium Reports
Oncology 2020

Oncology 2020
A Comprehensive Look at Medical Oncology and Radiation Therapy Solutions

September 29, 2020 | Read Time: 7  minutes

Current Time Inside Cache Tag Helper: 4/11/2021 3:35:58 AM and Model.reportId = 1665

An estimated 1.8 million new cancer cases will be diagnosed in the United States in 2020. In order to treat cancer at these volumes and achieve the best outcomes for patients, healthcare organizations—including comprehensive cancer centers, community oncology practices, and oncology facilities associated with acute care hospitals—need oncology software and equipment with up-to-date functionality, strong integration, and good vendor support. With the goal of helping healthcare organizations understand their options, this report provides a comprehensive look at the oncology IT market, examining customer satisfaction with medical oncology software, radiation oncology software, radiation therapy equipment, and treatment planning software.
† See

Healthcare Providers,
Want to see full details?

Not a Provider, contact us for pricing details.

Current Time Inside Cache Tag Helper: 4/11/2021 3:35:58 AM and Model.reportId = 1665

Key Findings:

  1. Oncology Vendor Landscape
  2. Elekta Leads in Medical Oncology Functionality and Integration, Followed by Epic
  3. McKesson Does Well with Training; Varian, Epic, and Cerner Customers Struggle with Workflows
  4. Culture, Value the Biggest Differentiators, with Elekta Ahead of Varian in Both
  5. Elekta Delivers High Value and Relationships; Accuray Trails the Market
  6. Over Half of Philips Customers Don’t Plan to Stay
 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2021 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.